Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.

Key facts

Study ID

NCT00002574

Run by

National Cancer Institute (NCI)

People needed

87

Starts

1994-09-01

Last updated by the study team

2013-02-05

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.